Urology

SPECIALTY SEGMENT

Urology

Urology is the branch of medicine focused on the urinary tract system — kidneys, ureters, bladder and urethra — as well as the male reproductive system. Urological conditions range from urinary tract infections and kidney stones to benign prostatic hyperplasia (BPH), gout and overactive bladder.

In India, urological disorders are increasingly common — yet many go undiagnosed or undertreated due to stigma, low awareness and limited access to specialist care. Benign prostatic hyperplasia alone affects nearly 50% of Indian men over 50. Gout prevalence is rising rapidly with changing diets and lifestyle patterns.

At Quinek Life Sciences, our Urology segment provides specialists with a targeted range of WHO-GMP certified medicines — from alpha blockers and combination BPH therapies to gout management, UTI treatment and overactive bladder care.

50% of Men

Over 50 affected by BPH in India

40% Rise

In gout cases in India over last decade

10 Products

Across 5 urology categories

THE REALITY

Urological Health in India — The Numbers

50%

Men Over 50 Have BPH

Benign Prostatic Hyperplasia is the most common urological condition in Indian men

40%

Rise in Gout Cases

Gout prevalence has risen 40% in India in the last decade driven by diet and lifestyle changes

150M+

UTI Cases Annually

India records over 150 million UTI cases per year — primarily affecting women and elderly men

30%

Overactive Bladder

Nearly 1 in 3 adults over 40 in India experiences overactive bladder symptoms

WHY WE BUILT THIS SEGMENT

BPH Cases in India — Rising with an Ageing Population

As India’s population ages, the burden of benign prostatic hyperplasia is growing rapidly. BPH significantly impacts quality of life — causing urinary obstruction, nocturia and increasing the risk of acute urinary retention. Early treatment with quality alpha blockers and combination therapies is essential.

Reported BPH Cases (millions)
Projected if unaddressed
35M

2019

40M

2020

45M

2021

50M

2022

55M

2023

60M

2024

66M

2025

72M

2026

78M

2027

85M

2028

Based on USI, ICMR data — BPH prevalence India 2019–2028

OUR RANGE

Urology Medicine Categories

🔵

Alpha Blockers — BPH Management

Relieves urinary obstruction in benign prostatic hyperplasia

DOSI-Q4

Silodosin 4mg

DOSI-Q8

Silodosin 8mg

DOSI-QDT

Silodosin 8mg + Dutasteride 0.5mg

🧬

Gout Management

Reduces uric acid levels in gout and hyperuricaemia

Q-STAT 40

Febuxostat 40mg

Q-STAT 80

Febuxostat 80mg

💊

BPH Combination Therapy

Dual-action therapy for advanced BPH management

TAMS-RIDE

Tamsulosin 0.4mg + Dutasteride 0.5mg

ALFURIDE

Alfuzosin HCl 10mg + Dutasteride 0.5mg

🛡️

UTI Treatment

Treats urinary tract infections effectively

ORA-Q

Nitrofurantoin Sustained Release 100mg

💧

Overactive Bladder

Controls urgency, frequency and urge incontinence

OLIF-Q10

Solifenacin Succinate 10mg

OLIF-Q5

Solifenacin Succinate 5mg

“Better urological care starts with better medicines. We are here to make that possible.”

— QUINEK LIFE SCIENCES